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ScienceDirectKaposi’s Sarcoma-associated herpesvirus (KSHV) and Epstein
Barr virus (EBV) are the causative agents of several
malignancies. Like all herpesviruses, KSHV and EBV undergo
distinct latent and lytic replication programmes. The transition
between these states allows the establishment of a lifelong
persistent infection, dissemination to sites of disease and the
spread to new hosts. Latency-associated viral proteins have
been well characterised in transformation and tumourigenesis
pathways; however, a number of studies have shown that
abrogation of KSHV and EBV lytic gene expression impairs the
oncogenesis of several cancers. Furthermore, several lytically
expressed proteins have been functionally tethered to the
angioproliferative and anti-apoptotic phenotypes of virus-
infected cells. As a result, the investigation and therapeutic
targeting of KSHV and EBV lytic cycles may be essential for the
treatment of their associated malignancies.
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Introduction
Kaposi’s sarcoma associated herpesvirus (KSHV) and
Epstein Barr virus (EBV) are double stranded gamma-
herpesviruses which contribute to the oncogenesis of
several human tumours. KSHV is the etiological agent
of the endothelial cell tumour Kaposi’s Sarcoma, in
addition to two lymphoproliferative disorders; primary
effusion lymphoma (PEL) and multicentric
Castleman’s disease (MCD) [1–3]. Whereas, EBV hasCurrent Opinion in Virology 2018, 32:60–70 been linked with multiple malignancies including
Burkitt’s lymphoma (BL), Hodgkin’s lymphoma
(HL), nasopharyngeal carcinoma (NPC) and gastric
carcinoma (GC) [4–6].
Like all herpesviruses, KSHV and EBV have a biphasic
life cycle comprising latent and lytic replication pro-
grammes. During latency, both viruses exist in a dormant
state where only a subset of the viral genes are expressed
facilitating the episomal persistence of the viral genome
[7,8]. However, under certain physiological conditions,
both viruses undergo lytic reactivation leading to expres-
sion of the full complement of lytic genes followed by
the assembly and egress of infectious virions. Impor-
tantly however, both KSHV and EBV can also undergo
abortive lytic reactivation, resulting in the expression of
early lytic genes without subsequent virion assembly and
cell lysis.
Although much of the efforts to understand the molecular
basis of these disorders has focused on viral latency,
KSHV and EBV lytic cycles are now widely accepted
as major contributors to oncogenesis which could be
important targets in the development of anti-cancer ther-
apeutics [9,10]. Thus, in this review, we discuss how lytic
replication augments the pathogenesis of KSHV and
EBV-associated malignancies (Figure 1) and the treat-
ments available which may target the lytic replication
cycle.
KSHV lytic factors and tumourigenesis
Expression of the KSHV major lytic transactivator, RTA,
is sufficient and necessary to activate the KSHV lytic
cycle leading to a triphasic transcriptional cascade of
immediate early, delayed early and late gene expression
[11,12]. To initiate the transition from latency to lytic
replication, a range of stimuli have been implicated
including hypoxia, co-infection with HIV-1, oxidative
stress and inflammatory cytokines; all of which promote
the expression of RTA [13–16]. Importantly, the treat-
ment of KS patients with drugs that prevent lytic replica-
tion can, in certain cases, lead to regression of KS lesions;
attesting to the importance of lytic gene expression in
tumourigenesis [17].
Although in vivo, the spontaneous reactivation of
KSHV takes place in only 1–3% of infected cells, the
resultant assembly and egress of KSHV infectiouswww.sciencedirect.com
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Schematic representation how KSHV and EBV lytically expressed proteins augment the pathogenesis of KSHV and EBV-associated malignancies.particles sustains the population of latently infected
cells that would otherwise be lost due to a combination
of defects in episome synthesis during cell division and
the death of infected cells [18]. Therefore, the balance
between KSHV latent and lytic replication pro-
grammes is stringently controlled to ensure viral per-
sistence and consequently tumour development. Nev-
ertheless, in addition to the role of the lytic cycle in
supporting a lifelong, persistent KSHV infection, a
number of lytic factors themselves have oncogenic
properties [19] (Table 1). Thus, the following section
will outline these oncogenic lytic genes and discuss
how they contribute to malignancy alongside their role
in viral replication.
vGPCR
Viral G-protein-coupled-receptor (vGPCR) is an early
lytic protein encoded by the viral gene ORF74. It shares
limited homology to the human interleukin-8 receptors
CXCR1 and CXCR2; however, ORF74 is constitutively
active and minimally responsive to various ligands
[20,21]. vGPCR activates members of the G protein
family which stimulate several major cell signalling path-
ways such as phosphatidylinositol 3-kinase (PI3K), phos-
phoinoside-dependent kinase (PDK) and AKT/proteinwww.sciencedirect.com kinase B (AKT/PKB) along with several small GTPase
proteins such as RhoA and Rac1 [22–25]. The induction
of a myriad of signalling pathways which activate Sp1/3
transcription factors is crucial to the maintenance of RTA
expression and therefore commits the cell to productive
lytic replication [26,27]. Previous studies have demon-
strated that vGPCR is an oncogene capable of inducing
angioproliferative lesions in transgenic mice that bear the
pathological indicators of KS [28]. The angioproliferative
nature of vGPCR appears to stem from its indirect
production and secretion of a number of paracrine sig-
nalling molecules such as vascular endothelial growth
factor (VEGF) [22–25]. As a result, it has been suggested
that vGPCR initiates the immortalisation of endothelial
cells and KS tumourigenesis through the establishment
of a VEGF paracrine loop [28]. In this proposed ‘hit and
run’ model of immortalisation, populations of lytically
replicating endothelial cells express vGPCR leading to
VEGF expression and secretion. This acts in an auto-
crine mechanism on lytically replicating cells but also in
a paracrine fashion on adjacent latently infected cells to
promote their survival and immortalisation.Current Opinion in Virology 2018, 32:60–70
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Table 1
KSHV lytic oncogenes and mechanisms of tumorigenesis
KSHV lytic
gene
Cellular
homologue
Lytic function Mechanisms of oncogenesis Oncogenic
function
Reference
vGPRCR
IL-8 receptor
Activates cellular
signalling pathways to
maintain Rta expression
Secretes paracrine signalling molecules such as
VEGF
Cell survival,
angiogenesis
[22–25,28]Activates Rho and Rac1 GTPases
Stimulates PI3K, PDK, AKT/PKB, p38 and MAPK
signalling pathways
K1
BCR
Activates cellular
signalling pathways to
maintain Rta expression
Contributes to VEGF autocrine and paracrine
signalling
Cell survival,
angiogenesis
[31–35,36]Perturbs normal PI3K and MAPK signalling
Activates AKT and mTOR
Interacts with HIV-1 Tat to activate NF-kB
K15 Activates cellular
signalling pathways
Modulates PLCg-Calcineurin-NFAT pathways
Angiogenesis [37,38]Chemokine and cytokine production
vIL-6
IL-6
Immune evasion and
activation of cellular
signalling pathways
Activates JAK/STAT, MAPK and PI3K/AKT
pathways Proliferation and
angiogenesis
[40–43]Contributes to VEGF autocrine and paracrine
signalling
vIRFs
IRFs Immunoevasins
Inhibits Interferon a/b/g responses and
inflammatory signalling
Cell survival [39,44–47]Interaction with p53 prevents ATM/p53 DNA
damage response pathway
vBCL-2 BCL-2 Delays cell death Inhibits apoptosis and autophagy Cell survival [48–50,51,52]
vCCLs
CCLs Immunoevasins
Modulation of CCL activity
Angiogenesis [53–55]Chemoattractants for TH2 cells to reduce TH1 cell
activity
RTA Lytic transactivator Induction of DNA damage Genome
instability
[60]
ORF57 Processing, export and
translation of viral RNAs
Sequesters the transcription and export complex
(hTREX) to cause R-loop formation and DSBs
Genome
instability
[57,58,59]K1 and K15
ORF-K1 encodes a type 1 transmembrane glycoprotein
which shares structural similarities with the B cell recep-
tor (BCR) [29]. The lytic protein appears to contribute to
KSHV lytic replication in a similar manner to vGPCR
through the maintenance of RTA expression; however,
the specific mechanism behind this is not well understood
[30]. Like vGPCR, K1 expression also contributes to the
VEGF autocrine and paracrine signalling loop through its
constitutively active ITAM domain, promoting the pro-
duction and secretion of VEGF via matrix metallopro-
tease 9 (MMP-9) [31–33]. Increased VEGF signalling
modulates downstream pathways such as PI3K and mito-
gen activated kinase which in turn activate Akt kinase and
mammalian target of rapamycin (mTOR) to promote cell
survival [32,34,35]. Furthermore, K1 has also been shown
to interact with the HIV-1 protein Tat. Mouse studies
have shown that coexpression of K1 and HIV-1 Tat leads
to a synergistic increase in angiogenesis through the Tat-
mediated upregulation of host microRNA miR-891a-5b
which targets NF-kb [36].
Like ORF-K1, KSHV ORF-K15 encodes a transmem-
brane receptor which antagonises BCR signalling; how-
ever, K15 lack an ITAM domain and activates the pro-
duction of cytokines and chemokines via cellular
signalling pathways including NF-kB, MEK/ERK andCurrent Opinion in Virology 2018, 32:60–70 Jun N-terminal protein kinase (JNK) pathways [37]. K15
bypasses the induction of VEGF signalling by activating
the downstream PLCg-Calcineurin-NFAT pathways to
facilitate angiogenic tube formation in cell culture [38]. It
is speculated that K15 is involved in the early develop-
ment of KS tumour where limited lytic gene expression is
detected [38].
KSHV immunoevasins
Successful KSHV lytic replication is dependent on the
expression of viral interferon regulatory factors (IRFs)
and viral interleukins (IL) which prevent immune detec-
tion [39]. Most of these viral proteins are expressed during
lytic replication to inhibit the interferon (IFN) antiviral
response. KSHV vIL-6, like its human homologue can
bind the gp130 receptor and activate the JAK/STAT,
MAPK and PI3K/Akt cellular signalling pathways leading
to expression of hIL-6 and VEGF [40–42]. Furthermore,
the inoculation of NIH3T3 cells ectopically expressing
vIL-6 into immunocompromised mice leads to tumour
formation and vIL-6 expression in endothelial cells leads
to angioproliferation and tubule formation [43].
The KSHV genome also possesses three lytically encoded
vIRF ORFs: ORF-K9, ORF-K11/K11.1 and ORF-K10
encoding vIRF1, vIRF2 and vIRF4 respectively [39,44].
vIRFs act to disrupt the antiviral IFN response bywww.sciencedirect.com
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signals. The mechanism of vIRF action varies between
isoforms; however, in many cases vIRF bind to cellular
IRFs and inhibit their ability to activate transcription [39].
Through the dysregulation of the IFN antiviral response,
apoptosis and cell cycle arrest are prevented increasing
the oncogenic potential of KSHV-infected cells [44,45].
vIRF1 co-precipitates with p53, reducing p53 target gene
expression [46]. Studies have demonstrated this vIRF1-
p53 is crucial for the inhibition of the ATM/p53 DNA
damage response pathway allowing viral DNA replication
to proceed [39,46,47]. vIRF1 appears to block activation
of ATM and decreases p53 stability through reduced
phosphorylation of Ser15 of p53 [47].
vBcl-2
vBcl-2, encoded by KSHV ORF16 shares sequence and
functional homology to the Bcl-2 family of cellular pro-
teins [48]. Normally, Bcl-2 proteins act as regulators of
apoptosis and are characterised by four conserved
stretches of amino acids called Bcl-2 homology (BH)
domains [49]. Cellular Bcl-2 also negatively regulates
autophagy by interacting with autophagy promoting fac-
tor Beclin-2 [50]. Studies in the murine counterpart of
KSHV, murine herpesvirus 68 (MHV68), have shown that
vBcl-2 is involved in both the inhibition of autophagy and
apoptosis to promote B cell survival [51]. The impor-
tance of autophagy in programmed cell death makes it an
important target for KSHV during lytic infection to pre-
vent induction of apoptosis and thus the impairment of
viral replication. In KSHV the function of vBcl-2 has not
yet been fully elucidated; however, lack of vBcl-2 impairs
KSHV reactivation [48,52].
vCCLs
KSHV also encodes three homologues of cellular che-
mokines known as viral CC-chemokine ligands (vCCLs)
[53]. Previous studies have shown that vCCL1–vCCL3
are all able to bind to their cellular homologues both
agonistically and antagonistically to stimulate angiogen-
esis [53,54]. Furthermore, all three viral proteins have
been suggested to act as chemoattractants to modulate
the levels of different T-cell subpopulations in KS
lesions. The resultant TH2 cell-predominant tumour
microenvironment in which TH1 cell responses are
downregulated allowing immune evasion and thus
tumour progression [55].
KSHV and genome instability
KSHV lytic replication is associated with the formation of
double strand-breaks (DSBs) and chromosomal aberra-
tions, which are a common feature of KS lesions [56]. The
KSHV early protein ORF57 controls the processing,
export and translation of viral RNAs [57,58]. However,
studies have shown that sequestration of the human
transcription and export complex (hTREX) by ORF57
leads to DSBs as a result of R-loop formation [59].www.sciencedirect.com Furthermore, studies have suggested that Rta is also able
to induce DNA damage [60]. Importantly, the activation
of members of the DNA damage response machinery in
this way has been suggested to facilitate viral DNA
synthesis during productive lytic replication; as is the
case with other Herpesviruses [60]. Thus, the role of
KSHV lytic factors in genome instability likely contrib-
utes to oncogenesis.
EBV lytic factors and tumourigenesis
EBV establishes a lifelong infection in B lymphocytes
achieved through a highly regulated viral gene expression
program. In latently infected B cells, the expression of
either Zta or Rta is sufficient to reactivate the EBV lytic
cycle [61–64]. Lytic replication can be studied by treating
latently infected B cells with inducers of the lytic cycle
such as phorbal esters or by crosslinking B cell receptors
with anti-immunoglobulins [65,66]. There have been
several important insights regarding the contribution of
the EBV lytic cycle for virus-induced tumorigenesis in
vivo. Mouse models have demonstrated that lytic repli-
cation incompetent-EBV particles are impaired in their
ability to cause lymphomagenesis compared to wild type
virus, despite similar infection levels [67]. Furthermore,
acyclovir treatment, which blocks lytic viral genome
replication but not lytic gene expression, is unable to
prevent EBV associated lymphomagenesis; reinforcing
the role of lytic cycle-induced paracrine signals in disease
progression [68]. Finally, in vivo studies have shown that
in KSHV-infected PEL cells, tumour formation is
enhanced upon coinfection with EBV [69]. Together,
these studies strongly support the view that lytic gene
expression is important for tumour progression, and that
paracrine signals play an essential role.
Similar to KSHV and the role of lytic reactivation in KS,
reactivation of EBV may aid transmission of the virus
within the tumor microenvironment to establish latency
and drive cellular proliferation. However, the likely pre-
dominant role of the EBV lytic cycle is to provide the
necessary paracrine, anti-apoptotic and immunomodula-
tory signals required for tumorigenesis (Table 2).
ZTA
Various studies have shown that the expression of some
lytic antigens alone is sufficient to induce the expression
of immunomodulatory and paracrine factors associated
with oncogenesis. The lytic transactivator Zta facilitates
the secretion of IL-6, IL-8, IL-10 and IL-13 in addition to
proangiogenic proteins such as vascular endothelial
growth factor (VEGF) [67,68,70]. Soluble Zta has also
been detected in the sera of post-transplant lymphopro-
liferative disease (PTLD) patients providing further evi-
dence of a transformative role for this lytic protein [70].
Finally, Zta alone can downregulate the expression of
CIITA, an essential transcription factor important forCurrent Opinion in Virology 2018, 32:60–70
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Table 2
EBV lytic oncogenes and mechanisms of tumorigenesis
EBV lytic gene Cellular
homologue
Lytic function Mechanisms of oncogenesis Oncogenic function Reference
ZTA Lytic transactivator Promotes secretion of
proangiogenic factors IL-6, IL-8,
IL-10, IL-13 and VEGF
Angiogenesis [67,68,70,71]
BHRF1 and BALF1 BCL-2 Delay cell death Inhibition of apoptosis Cell survival [73,74]
BILF1 Immunoevasin Unknown but detected in EBV
tumours
[82,83]
BNFR1 Nucleocapsid trafficking Interacts with centromeres to
cause centrosome
overduplication
Genome instability [85]
BALF3 Terminase DNA synthesis and
incorporation into virons
DNA damage Genome instability [88]
BGLF4 Viral DNA replication and
nuclear import of viral
proteins
DNA damage Genome instability [86]
BGLF5 Host cell shut-off DNA damage Genome instability [79–81,87]
BARF1 C-fms receptor Immunomodulator Modulates expression genes
involved in apoptotic signalling
Cell survival [76,77]
BCRF1 IL-10 Immunoevasin Downregulates interferon g Cell survival [75]HLA-II expression permitting immune evasion and
tumour progression [71].
EBV and anti-apoptotic signalling
In addition to the paracrine effect, some lytic proteins
elicit strong anti-apoptotic signals [72]. Like KSHV
vBcl-2, the EBV lytic cycle-associated proteins BHRF1
and BALF1 are viral homologs of cellular Bcl-2 which
perform anti-apoptotic functions critical for cellular
transformation in vitro [73,74]. Similarly, BCRF1,
which is analogous to cellular IL-10, increases the
viability and transformation of EBV-infected B cells
through downregulation of interferon-g [75]. Finally,
BARF1 is one of the most highly expressed genes in
NPC cell lines and antibodies are frequently detected
in NPC-patient sera [73]. The encoded protein,
BARF1, a homolog of colony-stimulating factor 1 recep-
tor, is a secreted anti-apoptotic factor which influences
the survival of neighbouring cells [76,77]. Taken
together, these studies implicate anti-apoptotic signal-
ling by EBV lytic proteins in the oncogenesis of EBV-
associated malignancies. However, although the
expression of BHRF1, BALF1 and BARF1 is dramati-
cally increased during lytic reactivation, and they have
previously been designated as lytic genes, their expres-
sion has been detected in LCLs (lymphoblastoid cell
lines) where cells are predominantly latently infected
(>95%) [78]. Furthermore, BHRF1 is expressed from
the latent promoter Wp in a subset of BL known as Wp-
restricted BL [78]. Therefore, it is unclear whether
these proteins contribute to tumorigenesis during the
latent or lytic life cycles.Current Opinion in Virology 2018, 32:60–70 BGLF5 and BILF1 immunoevasins
Several EBV lytic proteins, which primarily function as
immunoevasins, also contribute to tumorigenesis.
BGLF5, the EBV host shut-off protein which inhibits
translation of host mRNAs, functions in the downregula-
tion of toll-like receptor 9 (TLR9) and human leukocyte
antigen class I (HLA-I) and –II leading to impaired T cell
recognition [79,80]. Importantly however, BGLF5
expression has been detected in NPC biopsies and
BGLF5 antibodies have been detected in NPC patient
sera, suggesting the protein also undertakes a transforma-
tive role [81]. Similarly, the lytic EBV immunoevasin
BILF1 enhances the internalisation of surface molecules
of HLA-I leading to their rapid degradation by the lyso-
some; again impairing T cell recognition [82]. However,
BILF1 expression has also been detected in NPC cells,
once again suggesting an oncogenic function [83].
EBV and genomic instability
Like KSHV, several EBV lytic proteins have also been
implicated as contributors to genomic instability [84]. A
recent study suggested that the EBV major tegument
protein, BNFR1, involved in translocation of the viral
nucleocapsid to the nucleus, induces centrosome ampli-
fication and thus contributes to the accumulation of
chromosomal aberrations in infected cells [85]. Further-
more, BNFR1 was able to induce genomic instability
within latently infected LCLs without necessarily estab-
lishing infection, demonstrating that EBV lytic replica-
tion can promote transformation in adjacent cells [85].
Three further EBV proteins, BALF3, BGLF4 and host
cell-shutoff protein BGLF5 have all been suggested to
further contribute to chromosomal instability andwww.sciencedirect.com
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NPC cells [86–88]. Thus, genomic instability appears a
major mechanism through which EBV lytic proteins
contribute to oncogenesis.
Treatments for KSHV and EBV-associated
cancers
Considerable advances in the understanding of the KSHV
and EBV life cycle and related pathologies have been
made since their discovery, however, presently there are
still no vaccines or effective direct therapeutic options
available for the prevention or treatment of their associ-
ated cancers. Almost all clinically available therapies that
target the lytic life cycle of KSHV and EBV do not
directly inhibit the virus and have shown varying results
in the clinic (Table 3). Because of the critical role of lytic
replication in disease progression and virus dissemination
these highlight the need for potent and selective thera-
peutics against lytic viral targets to treat KSHV and EBV-
associated cancers.
There is no standard of care for the treatment of KSHV-
associated tumours and current options range from target-
ing cancers through surgical excision, chemotherapy and
radiotherapy [89]. These treatment options are also
recommended for EBV-associated cancers however,
due to the array of cancers associated with EBV, treat-
ment guidelines vary greatly for each different associated
cancer [90].
To date, the most effective treatment of AIDS-related KS
and AIDS-related EBV-associated cancers is highly active
antiretroviral therapy (HAART), which works mostly
through restoration of the patient’s immune system
[91]. Likewise, iatrogenic KS, MCD, PEL and iatrogenic
EBV-associated sarcomas and lymphomas are treated
through the removal of immunosuppressants, to restore
the patient’s immune system, limiting tumour progres-
sion, however this in turn can lead to graft rejection [92].
Immunotherapies have also been demonstrated to be
effective at treating KSHV and EBV-associated cancers.
Rituximab (anti-CD20) is clinically approved for the
treatment of many EBV-associated lymphoproliferative
diseases and also MCD [93,94]. In addition, Tocilizu-
mab (anti-human IL-6 receptor) and Siltuximab (anti-IL6
chimeric monoclonal antibody) are clinically available for
the treatment of MCD [95,96].
Novel therapies involving lytic KSHV and EBV
The majority of cells present in KSHV and EBV-associ-
ated cancers are latently infected therefore, there is
substantial research exploring the potential of lytic induc-
tion therapy to treat these cancers. This treatment
involves the efficient induction of all latently infected
tumour cells into the lytic cycle while concomitantly
exposing the cells to inhibitors of lytic replication andwww.sciencedirect.com inducing apoptosis to clear all virally infected cells. In
addition, lytic induction therapy can help induce a cyto-
toxic T-lymphocyte (CTL) response to lytic antigens to
further clear cancerous virally infected cells. Lytic induc-
tion therapy poses a powerful mechanism to enhance the
efficacy of EBV and KSHV lytic inhibitors, which are
discussed below.
Because of the critical role of the KSHV and EBV lytic life
cycle in tumorigenesis there is considerable interest in
developing vaccines that target lytic antigens [97]. Vari-
ous vaccines have been created targeting a range of lytic
KSHV and EBV antigens. Some of these vaccines have
proved successful in vivo and in clinical trials, such as the
EBV envelope protein gp350, which reduced primary
infection however, the vaccine failed to decrease the
overall EBV infection rate.
Finally, cytokine therapy can induced protective T-cell
immunity against viruses. Cytokine therapy in a huma-
nised mouse model with EBV-associated lymphoproli-
ferative disease induced a marked expansion of Zta-
specific T-cells, which can prolong survival [98,99]. In
addition to supporting the notion that Zta plays a critical
role in lymphoproliferative disease, it provides a strong
rationale for the inclusion of Zta-specific antigens in
vaccine development [97].
KSHV and EBV lytic inhibitors
The lytic life cycles of KSHV and EBV pose numerous
attractive and viable targets for the development of anti-
viral drugs. However, the only KSHV and EBV inhibitors
clinically available (and all anti-herpesvirus drugs in
general) target the viral DNA-polymerase [100]. The
most common of these drugs are nucleoside analogues,
but acyclic nucleoside phosphonates (ANPs) and pyro-
phosphate analogues are also frequently used for herpes-
virus therapy [89]. Clinically available nucleoside analo-
gues are administered as pro-drugs and only activated by
the viral thymidine kinase present during lytic replication
[101]. Novel viral DNA-polymerase inhibitors have also
been developed such as, second and third generation,
nucleoside analogues and ANPs, and non-nucleoside
inhibitors [102,103].
Many other inhibitors of herpesvirus replication have also
been explored which target numerous aspects of the lytic
life cycle, however none have made it as yet into the
clinic. Targets with inhibitors demonstrated to have
efficacy against EBV and KSHV include, the KSHV
latent-lytic transactivator RTA, KSHV IRFs and the viral
capsid protease [104,105].
Cellular targets required for lytic reactivation of EBV and
KSHV and that contribute to lytic EBV and KSHV-
associated tumorigenesis have also been approached as
targets for inhibitors of their associated cancers [106].Current Opinion in Virology 2018, 32:60–70
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Table 3
Current treatments and inhibitors targeting the lytic life cycles of KSHV and EBV-associated cancers. Stage of development abbreviations: R=Randomised, C=Control and SP=Single
Patient. Clinical disease abbreviations: HSV=Herpes simplex virus, VZV=Varicella zoster virus, CMV=Cytomegalovirus, HBV=Hepatitis B virus, ML=Myeloid leukaemia, ALL=Acute
lymphoblastic leukaemia, LAM=Lymphangioleiomyomatosis, MDS=Myelodysplastic syndromes, CMML=Chronic myelomonocytic leukaemia and CTCL=Cutaneous T-cell
lymphoma
Therpay target Inhibitor class Inhibitor subclass Drug Stage of development Already clinically
approved for:
KSHV EBV
Viral DNA polymerase
Nucleoside analogues
Purine analogues
Acyclovir Cohort study In vitro HSV and VZV
Valganciclovir R, C trial SP study CMV
Pyrimidine analogs Zidovudine R trial In vivo HIV
Methylenecyclopropane
nucleosides
Cyclopropavir In vitro In vitro None
Acyclic nucleoside
phosphonates
HPMP derivatives Cidofovir Pilot study In vivo CMV
PME derivatives Adefovir In vitro In vitro HBV
Pyrophosphate analog Foscarnet sodium Cohort study In vitro CMV
Non-nucleoside inhibitor Pyrimidoquinoline analog NSC 373989 In vitro None None
Viral mRNAs
Peptide-conjugated
phosphorodiamidate morpholin
oligomers (PPMO)
PPMO against
RTA
In vivo n/a None
PPMO against
vIRF-1
In vitro n/a None
Viral capsid protease Small molecule helical mimetic Dimerisation inhibitor DD2 In vitro In vitro None
Lytic repression
Small-molecule inhibitors
Stilbenoid Resveratrol In vitro In vitro Dietary supplement
Lipid Delta-9 tetrahydrocannabinol
In vitro In vitro Multiple sclerosis
Ephrin receptor
tyrosine kinase A2
Small-molecule inhibitors
ATP-competitive tyrosine
kinase inhibitor
Dasatinib In vitro Phase I trial Chronic ML and ALL
4-(2,5-dimethyl-
pyrrol-1-yl)-2-
hydroxy-benzoic
acid
In vitro None None
Dihydroorotate
dehydrogenase/p53
Small-molecule inhibitor Teriflunomide None In vitro Multiple sclerosis
HSP70 Small-molecule inhibitor ATP-derivative inhibitor VER-155008 In vitro None None
hTREX Small-molecule inhibitor ATPase inhibitor CCT018159 In vitro None None
mTOR Polyketide Rapamycin Phase I trial In vivo Organ transplant
rejection and LAM
Lytic induction Cytidine analogue DNA demethylation agent 5-azacytidine In vitro In vitro MDS, Acute ML and
CMML
Small-molecule inhibitor
N-protected dipeptide Bortezomib In vivo In vitro Multiple myeloma
Neddylation inhibitor Pevonedistat In vitro In vitro None
Lipid Valproic acid In vitro Pilot study Anticonvulsant
Histone deacetylase inhibitor Suberoylanilide
hydroxamic acid
In vivo In vivo CTCL
C7 None In vitro None
Protective T-cell
immunity
Vaccine
Capsid protein gp350 n/a Phase II trial None
Replication-competent viruses Latency deficient
replication-
competent
viruses
In vivo None None
Cytokine therapy GM-CSF and IL-2 None In vivo None
C
u
rre
n
t
 O
p
in
io
n
 in
 V
iro
lo
g
y
 2
0
1
8
,
 3
2
:6
0
–
7
0
 
w
w
w
.s
c
ie
n
c
e
d
ire
c
t.c
o
m
Gammaherpesvirus lytic oncogenes Manners et al. 67Cellular inhibitors bear an increased risk of cytotoxic side
effects, however, they possess great advantages due to
fewer occurrences of drug-resistance and the potential for
a broader activity against a range of viruses. Targets
include, the KSHV/EBV cellular entry receptor (ephrin
receptor tyrosine kinase A2), the proteasome, Hsp70, the
human transcription/export complex (hTREX), the mam-
malian target of rapamycin (mTOR) and the dihydroor-
otate dehydrogenase enzyme [106,107,108,109,
110,111]. While most inhibitors of cellular targets have
only been demonstrated in vitro some have also shown
efficacy in the clinic.
All clinically available inhibitors of EBV and KSHV have
low efficacy and only target the viral DNA polymerase.
Therefore, more efforts should be invested to examine
the potential of drugs that target other viral proteins, since
this proof-of-principle has been shown beneficial for other
herpesviruses, such as HSV and HCMV.
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